[Skip to Content]

Upstate Active Clinical Trials

Study Title:

A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared with Insulin Degludec in Participants with Type 1 Diabetes Treated with Multiple Daily Injection Therapy.

What is the purpose of the study? (in Layman's terms, please describe the study)

The study is being done to see how safe a once-weekly investigational drug is and how it will work to help people with type 1 diabetes who are treated with multiple daily injections of insulin.

Upstate Institutional Review Board (IRB) Number:

1904064

Study/Protocol ID:

QWINT-5/I8H-MC-BDCY

Study Phase:

3

Patient Age Group:

Adults

Principal Investigator:

Ruth S Weinstock, MD, PhD

What is involved if I participate?

  • How long is the study?
    Participation lasts about 60 weeks.
  • Is transportation provided or reimbursed?
    Yes
  • Is parking provided or reimbursed?
    Yes
  • What tests and procedures are involved?
    Vital signs, physical exam, blood and urine tests, electrocardiogram (ECG), continuous glucose monitoring, questionnaires and electronic study diary completion, diabetes counseling.

Where will the study take place?

Clinical Research Unit at the Institute for Human Performance

Other Information:

Participants will be paid for completed study visits.

ClinicalTrials.Gov ID:

NCT05463744

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Suzan M Bzdick, RN
Phone: 315-464-9006
Email: bzdicks@upstate.edu

Return to Previous Page || Search Again

Top